Eni’s low-beta profile stands out as Middle East tensions stir volatility, with three other screened names also showing recent gains and solid liquidity.
Source: https://www.zacks.com/stock/news/2898311/best-low-beta-stock…
Lumentum and Coherent have market caps of more than $40 billion, well above the threshold for S&P 500 inclusion.
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
The ongoing global turmoil and end of the earnings season have brought the market to a mixed trajectory.
